Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2010-02-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-010-0757-7PMID 20157776
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.

  2010cited by this paper
• San Antonio Breast Cancer Symposium.

  2009cited by this paper
• A Comparison of the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands and the Australian/Canadian Osteoarthritis Hand Index in Hand Osteoarthritis Patients

  2009influential reference
• Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.

  2009cited by this paper
• Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer

  2009cited by this paper
• Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivors

  2009cited by this paper
• Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia.

  2009cited by this paper
• Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.

  2009influential reference
• Feasibility Trial of Electroacupuncture for Aromatase Inhibitor—Related Arthralgia in Breast Cancer Survivors

  2009cited by this paper
• A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms.

  2009cited by this paper
• Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

  2008influential reference
• Role of oestrogen in the development of joint symptoms?

  2008cited by this paper
• Estrogen and progesterone receptors in carpal tunnel syndrome

  2008cited by this paper
• The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study

  2008influential reference
• Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.

  2008cited by this paper
• Selective estrogen receptor-β agonists repress transcription of proinflammatory genes

  2008cited by this paper
• Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.

  2008cited by this paper
• Getting a grip on aromatase inhibitor-associated arthralgias.

  2008cited by this paper
• Biomarkers in osteoarthritis

  2008cited by this paper
• Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.

  2008influential reference
• Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

  2008cited by this paper
• Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

  2008cited by this paper
• Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach.

  2008cited by this paper
• Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers

  2008cited by this paper
• Selective Estrogen Receptor-β Agonists Repress Transcription of Proinflammatory Genes1

  2008cited by this paper
• Oestrogen exhibits type II collagen protective effects and attenuates collagen‐induced arthritis in rats

  2008cited by this paper
• Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

  2008cited by this paper
• Comparing the prevalence of rheumatic diseases in China with the rest of the world

  2008cited by this paper
• There's many a slip twixt cup and lip: adherence issues in cancer therapy

  2008cited by this paper
• Aromatase inhibitors and musculoskeletal symptoms.

  2008cited by this paper
• Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors

  2008influential reference
• Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

  2007cited by this paper
• Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

  2007cited by this paper
• Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis

  2007cited by this paper
• Predictive markers in rapidly progressing rheumatoid arthritis.

  2007cited by this paper
• Ultrasound of the digital flexor system: Normal and pathological findings().

  2007cited by this paper
• Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.

  2007influential reference
• Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging

  2007cited by this paper
• Technology Insight: the role of color and power Doppler ultrasonography in rheumatology

  2007cited by this paper
• Adherence to Endocrine Therapy for Breast Cancer

  2007cited by this paper
• Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study

  2007cited by this paper
• Aromatase inhibitor-associated arthralgia syndrome.

  2007cited by this paper
• Validity and factor structure of the AUSCAN Osteoarthritis Hand Index in a community-based sample.

  2007cited by this paper
• Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients.

  2007cited by this paper
• Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.

  2007cited by this paper
• Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study

  2007cited by this paper
• The ne w e ngl and j our na l of medicine

  2006cited by this paper
• Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.

  2006cited by this paper
• Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.

  2006cited by this paper
• Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.

  2006cited by this paper
• Musculoskeletal Pain and Menopausal Status

  2006cited by this paper
• Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

  2006cited by this paper
• Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.

  2006cited by this paper
• Will steroidal aromatase inhibitors induce rheumatoid arthritis?

  2006cited by this paper
• Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation.

  2006cited by this paper
• Biomarkers in osteoarthritis.

  2006cited by this paper
• Estrogen carcinogenesis in breast cancer.

  2006cited by this paper
• Estrogen Receptor-β Is the Predominant Estrogen Receptor Subtype in Normal Human Synovia

  2006cited by this paper
• Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

  2006influential reference
• Natural history of menopause symptoms in primary care patients: a MetroNet study.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting.

  2005cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis

  2005cited by this paper
• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

  2005cited by this paper
• Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.

  2005cited by this paper
• Musculoskeletal ultrasound including definitions for ultrasonographic pathology.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands).

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.

  2004influential reference
• Aromatase inhibitors for breast cancer in postmenopausal women.

  2004cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• Imaging of the musculoskeletal system: magnetic resonance imaging, ultrasonography and computed tomography.

  2003cited by this paper
• Estrogens, cartilage, and osteoarthritis.

  2003cited by this paper
• Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

  2003cited by this paper
• Changes in proinflammatory cytokine activity after menopause.

  2002cited by this paper
• Aromatase in synovial cells from postmenopausal women.

  2001cited by this paper
• Guidelines for musculoskeletal ultrasound in rheumatology

  2001cited by this paper
• The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

  2000cited by this paper
• Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

  2000cited by this paper
• Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors

  1999cited by this paper
• A meta-analytic review of pain perception across the menstrual cycle.

  1999cited by this paper
• The menopause.

  1999cited by this paper
• Arthritis at the Menopause

  1999cited by this paper
• Aromatase in Human Bone Tissue

  1997cited by this paper
• Factors associated with joint pain among postmenopausal women

  1997cited by this paper
• Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.

  1997cited by this paper
• Involvement of spinal cord δ opiate receptors in the antinociception of gestation and its hormonal simulation

  1997cited by this paper
• Accuracy of the Jamar dynamometer.

  1993cited by this paper
• Exemestane (FCE 24304), a new steroidal aromatase inhibitor.

  1992cited by this paper
• Reliability and validity of grip and pinch strength evaluations.

  1984cited by this paper
• The menopause.

  1965cited by this paper
• Arthritis of the menopause

  1928cited by this paper
• ARTHRITIS OF THE MENOPAUSE: A STUDY OF FIFTY CASES

  1925cited by this paper

• Musculoskeletal symptoms associated with aromatase inhibitors in the treatment of early breast cancer: A scoping review of risk factors and outcomes

  2025cites this paper
• A cross-sectional study on knowledge, attitude and practice of osteoporosis prevention in patients with breast cancer undergoing endocrine therapy: A cross-sectional study

  2025cites this paper
• [99mTc]Tc-NTP 15 − 5, a new proteoglycan tracer for functional imaging of joint cartilage: phase I (CARSPECT)

  2025cites this paper
• Aromatase inhibitors evoke periorbital allodynia in mice via calcitonin gene-related peptide and its receptors in Schwann cells

  2024cites this paper
• Persistent pain management in an oncology population through pain neuroscience education, a multimodal program: PaiNEd randomized clinical trial protocol

  2023cites this paper
• Symptom experience in endocrine therapy for breast cancer patients: A qualitative systematic review and meta-synthesis

  2023cites this paper
• The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation

  2023cites this paper
• Computational method for aromatase-related proteins using machine learning approach

  2023cites this paper
• Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature

  2023cites this paper
• Aromatase Inhibitor Induced Musculoskeletal Inflammation is Observed Independent of Oophorectomy in a Novel Mouse Model

  2022cites this paper
• Strategies to mitigate the toxicity of cancer therapeutics.

  2022cites this paper
• Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model

  2022cites this paper
• Machine Learning-Assisted Prediction of the Biological Activity of Aromatase Inhibitors and Data Mining to Explore Similar Compounds

  2022cites this paper
• Assessment of 99mTc-NTP 15-5 uptake on cartilage, a new proteoglycan tracer: Study protocol for a phase I trial (CARSPECT)

  2022cites this paper
• The association between menopausal status and clinical outcomes of female patients with carpal tunnel release: a retrospective observational study

  2022cites this paper
• Light‐intensity and moderate‐to‐vigorous intensity physical activity among older adult breast cancer survivors with obesity: A narrative review

  2022cites this paper
• A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders.

  2021influential citation
• Pain in the Cancer Survivor.

  2021cites this paper
• Aromatase Inhibitor Musculoskeletal Syndrome

  2021cites this paper
• Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross-sectional study.

  2020cites this paper
• Post-mastectomy and post-breast conservation surgery pain syndrome: a review of etiologies, risk prediction, and trends in management.

  2020cites this paper
• Longer Times of Receipt of Adjuvant Endocrine Therapy Correspond to Improved Functional Capacity and Lower Adiposity in Women Receiving Adjuvant Therapy

  2019cites this paper
• Causes of sick leave, disability pension, and death following a breast cancer diagnosis in women of working age.

  2019cites this paper
• Primary antiphospholipid syndrome during aromatase inhibitors therapy

  2019cites this paper
• Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy

  2019cites this paper
• Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial on the Use of Uncaria tomentosa (Cat's Claw) for Aromatase Inhibitor-Induced Arthralgia: A Pilot Study

  2019cites this paper
• Treating Persistent Pain After Breast Cancer Surgery

  2019cites this paper
• Breast cancer survivorship care beyond local and systemic therapy.

  2019cites this paper
• Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women’s Health Initiative

  2018cites this paper
• Aromatase inhibitors (AIs) are the standard of care for treatment of both early and advanced hormone-sensitive breast cancer in postmenopausal women. Although AIs

  2018cites this paper
• Mandibular indexes and fractal properties on the panoramic radiographs of the patients using aromatase inhibitors.

  2018cites this paper
• Effects of the Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: A randomized, controlled clinical trial.

  2018cites this paper
• Sickness absence following breast cancer surgery: a two‐year follow‐up cohort study

  2018cites this paper
• Carpal Tunnel and Effects of Hormone Therapy Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women’s Health Initiative

  2018cites this paper
• Joint pain and falls among women with breast cancer on aromatase inhibitors

  2018cites this paper
• Grip Strength in Women Being Treated for Breast Cancer and Receiving Adjuvant Endocrine Therapy: Systematic Review

  2017cites this paper
• Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study

  2017cites this paper
• Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology

  2017cites this paper
• Auricular Point Acupressure to Manage Aromatase Inhibitor-Induced Arthralgia in Postmenopausal Breast Cancer Survivors: A Pilot Study.

  2017cites this paper
• Pain in cancer survivors; filling in the gaps

  2017influential citation
• Bodily Changes And Coping Strategies Due To Adjuvant Anti-Hormonal Breast Cancer Therapy-A Focus Group Study Research

  2016cites this paper
• Acupuncture for Aromatase Inhibitor–Induced Arthralgia

  2015cites this paper
• Acupuncture for Joint Symptoms Related to Aromatase Inhibitor Therapy in Postmenopausal Women with Early-Stage Breast Cancer: A Narrative Review

  2015cites this paper
• Breast Cancer Patients' Experiences and Reflections Regarding Information about Adjuvant Endocrine Therapy and its Side-Effects - A Focus Group Study

  2015cites this paper
• Investigating the effects of aromatase inhibitors on the musculoskeletal system

  2014cites this paper
• Aromatase Inhibitor Associated Musculoskeletal Symptoms are associated with Reduced Physical Activity among Breast Cancer Survivors

  2014cites this paper
• Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial

  2014cites this paper
• Does Aromatase Inhibitors Cause Sjogren’s Syndrome and Polyneuropathy?

  2014cites this paper
• Arthralgies et anti-aromatases ☆

  2014cites this paper
• Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population

  2014cites this paper
• Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.

  2014cites this paper
• The Effect of Pain on Physical Functioning After Breast Cancer Treatment: Development and Validation of an Assessment Tool

  2014cites this paper
• Arthralgia and aromatase inhibitors.

  2014cites this paper
• Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors

  2013cites this paper
• Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients: Prevalence, Impact, and Recognition by Healthcare Providers

  2013cites this paper
• Persistent pain after breast cancer treatment.

  2013cites this paper
• Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer

  2013cites this paper
• Aromatase inhibitor-induced arthralgia: a review.

  2013cites this paper
• Bilateral De Quervain Syndrome after Aromatase Inhibitor Administration: A Case Report and Review of the Literature

  2012cites this paper
• Arthralgies, effets secondaires des inhibiteurs de l’aromatase: fréquence, signification et conséquences

  2012cites this paper
• Therapeutic optimization of aromatase inhibitor–associated arthralgia: etiology, onset, resolution, and symptom management in early breast cancer

  2012cites this paper
• Cancer, physical activity, and exercise.

  2012cites this paper
• Prevalence of breast cancer treatment sequelae over 6 years of follow‐up

  2012cites this paper
• Etiology, assessment, and management of aromatase inhibitor-related musculoskeletal symptoms.

  2012cites this paper
• Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.

  2012cites this paper
• A prospective model of care for breast cancer rehabilitation: Bone health and arthralgias

  2012cites this paper
• Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS

  2012cites this paper
• Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer

  2011cites this paper
• Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

  2011cites this paper
• Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK.

  2011cites this paper
• A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.

  2011cites this paper
• Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women

  2011cites this paper
• New pharmacogenomic paradigm in breast cancer treatment.

  2010cites this paper
• Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study

  2010cites this paper
• [99mTc]Tc-NTP 15 – 5, a new proteoglycan tracer for functional imaging of joint cartilage: phase I (CARSPECT)

  year unknowncites this paper